Meeting
2011 ASCO Annual Meeting
Phase II clinical trial of oxaliplatin and bevacizumab in refractory metastatic germ cell tumors (GCT).
Authors
A. Jain
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN
A. Jain , M. J. Brames , D. J. Vaughn , L. H. Einhorn
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer
Track
Genitourinary Cancer
Sub Track
Germ Cell/Testicular
Clinical Trial Registration Number
NCT00393861
Citation
J Clin Oncol 29: 2011 (suppl; abstr 4579)
Abstract #
4579
Poster Bd #
2B
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Phase 2 trial of bevacizumab (BEV)/high-dose chemotherapy (HDC) with autologous stem-cell transplant (ASCT) for refractory germ-cell tumors (GCT).
First Author: Yago Nieto
Poster
2012 ASCO Annual Meeting
Phase II trial of bevacizumab (BEV)/high-dose chemotherapy (HDC) for refractory germ-cell tumors (GCT).
First Author: Yago Nieto
Poster
2017 ASCO Annual Meeting
Infusional gemcitabine + docetaxel/melphalan/carboplatin (GemDMC) ± bevacizumab (BEV) as an effective high-dose chemotherapy (HDC) regimen for refractory of poor-risk relapsed germ-cell tumors (GCT).
First Author: Yago Nieto
Poster
2014 ASCO Annual Meeting
Salvage chemotherapy for relapsed germ cell tumors: A phase II trial of gemcitabine, paclitaxel, ifosfamide, and cisplatin (Gem-TIP).
First Author: Matthew James Wheater